Autolus Thera

$3.96 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Autolus Thera

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.

Stock Analysis

last close $4.14
1-mo return -22.2%
3-mo return -29.8%
avg daily vol. 485.14T
52-week high 9.12
52-week low 4.11
market cap. $322M
forward pe -
annual div. -
roe -57.5%
ltg forecast -
dividend yield -
annual rev. $2M
inst own. 59.8%
baraka

Subscribe now for daily local and international financial news

Subscribe